Catalent (CTLT) Lifted to Buy at ValuEngine

Catalent (NYSE:CTLT) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, ValuEngine reports.

A number of other brokerages also recently commented on CTLT. First Analysis reissued an “outperform” rating and issued a $49.00 price objective on shares of Catalent in a research report on Tuesday, March 5th. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, April 9th. Finally, TheStreet raised shares of Catalent from a “c” rating to a “b-” rating in a research report on Wednesday, February 6th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $47.83.

Shares of CTLT traded up $5.15 during midday trading on Monday, reaching $44.41. The stock had a trading volume of 3,074,010 shares, compared to its average volume of 866,404. Catalent has a one year low of $29.23 and a one year high of $46.43. The company has a market cap of $5.75 billion, a PE ratio of 27.93, a price-to-earnings-growth ratio of 2.16 and a beta of 1.69. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.08 and a quick ratio of 1.63.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, February 5th. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.37 by $0.08. Catalent had a net margin of 5.48% and a return on equity of 17.42%. The company had revenue of $623.00 million during the quarter, compared to the consensus estimate of $608.38 million. During the same quarter last year, the firm posted $0.45 EPS. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Analysts expect that Catalent will post 1.69 earnings per share for the current year.

In other news, SVP Lance Miyamoto sold 43,619 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $42.49, for a total transaction of $1,853,371.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Aristippos Gennadios sold 3,392 shares of the firm’s stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $42.18, for a total transaction of $143,074.56. The disclosure for this sale can be found here. In the last three months, insiders sold 54,326 shares of company stock valued at $2,303,676. Insiders own 1.40% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sciencast Management LP acquired a new stake in shares of Catalent during the 1st quarter worth about $813,000. Retirement Systems of Alabama lifted its stake in shares of Catalent by 0.6% during the 1st quarter. Retirement Systems of Alabama now owns 189,578 shares of the company’s stock worth $7,695,000 after buying an additional 1,130 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Catalent by 1.0% during the 1st quarter. Louisiana State Employees Retirement System now owns 39,000 shares of the company’s stock worth $1,583,000 after buying an additional 400 shares during the last quarter. First Bank & Trust lifted its stake in shares of Catalent by 20.2% during the 1st quarter. First Bank & Trust now owns 5,528 shares of the company’s stock worth $224,000 after buying an additional 928 shares during the last quarter. Finally, We Are One Seven LLC lifted its stake in shares of Catalent by 97.2% during the 1st quarter. We Are One Seven LLC now owns 14,363 shares of the company’s stock worth $582,000 after buying an additional 7,078 shares during the last quarter. Institutional investors own 99.83% of the company’s stock.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Further Reading: Ex-Dividend

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.